PF 04531083

Name: PF 04531083
Brand: MedChemExpress
SKU: HY-105283
Rating: 4.5 (0 reviews)

Cat. No.: HY-105283 Pureza: 99.62%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

PF 04531083 is an orally active and selective Na_V1.8 blocker with an IC₅₀ of 0.7 μM. PF 04531083 is a blood-brain barrier (BBB) penetrant compound. PF 04531083 can be used for the research of respiratory system and neuropathic/inflammatory pain.

Para uso exclusivo en investigación. No vendemos a pacientes.

PF 04531083 Estructura química

No. CAS : 1079400-07-9

Tamaño	Stock	Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
200 mg	Obtener un presupuesto
500 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Other Forms of PF 04531083:

PF 04531083 (Standard) Obtener un presupuesto

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Sodium Channel:

Ver todas las isoformas

Na_v1.1 Na_v1.2 Na_v1.3 Na_v1.4 Na_v1.5 Na_v1.6 Na_v1.7 Na_v1.8 Na_v1.9

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

IC₅₀ & Target^[1]

Na_v1.8

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	0.19 μM Compound: 13	Inhibition of human Nav1.8/beta1 expressed in HEK293 cells by manual patch clamp electrophysiology Inhibition of human Nav1.8/beta1 expressed in HEK293 cells by manual patch clamp electrophysiology	[PMID: 26101568]
HEK293	IC₅₀	0.7 μM Compound: 13	Inhibition of human Nav1.8 expressed in HEK293 cells assessed as reduction in blue fluorescent signal by VSP-FRET assay Inhibition of human Nav1.8 expressed in HEK293 cells assessed as reduction in blue fluorescent signal by VSP-FRET assay	[PMID: 26101568]
HEK293	IC₅₀	36 μM Compound: 13	Inhibition of human Nav1.7 expressed in HEK293 cells by FRET assay Inhibition of human Nav1.7 expressed in HEK293 cells by FRET assay	[PMID: 26101568]
HEK293	IC₅₀	37 μM Compound: 13	Inhibition of human Nav1.1 expressed in HEK293 cells by IonWorks Quattro selectivity assay Inhibition of human Nav1.1 expressed in HEK293 cells by IonWorks Quattro selectivity assay	[PMID: 26101568]
HEK293	IC₅₀	37 μM Compound: 13	Inhibition of human Nav1.5 expressed in HEK293 cells by IonWorks Quattro selectivity assay Inhibition of human Nav1.5 expressed in HEK293 cells by IonWorks Quattro selectivity assay	[PMID: 26101568]

In Vitro

PF 04531083 (1 μM) stimulates baseline activity by ~50% and the firing response to 10% CO₂ in chemosensitive retrotrapezoid nucleus (RTN) neuron in a slice from a Tcf4^tr/+ mice^[3].
PF 04531083 blocks human Na_v1.8, hNa_v1.1, hNa_v1.5, hNa_v1.7, TTX-r rat DRG, TTX-R hDRG, hERG with IC₅₀ values of 0.19, 37, 37, 36, 0.54, 0.2, >30 μM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	Clearance (CL)	V_d	Bioavailability
Rat	1 mg/kg	i.v.	3.9 h	-	6.7 mL/min/kg	2.25 L/kg	-
Rat	2 mg/kg	p.o.	N.D.	1.3 h	11.4 mL/min/kg	-	59 %

In Vivo

PF 04531083 (1 mg/kg, i.v.; or 2 mg/kg, p.o.) is a low clearance compound with good bioavailability ∼60% in rats^[2].
PF 04531083 (40 mg/kg; 1.5 h) is efficacious in the tibial nerve transection (TNT) induced mechanical allodynia model in rat^[2].
PF 04531083 inhibits native tetrodotoxin-resistant (TTX-R) currents in rodent dorsal root ganglion (DRG) neurons with an IC₅₀ of 0.54 μM^[2].
PF 04531083 (40 mg/kg; 1.5 h) improves baseline breathing in Tcf4^tr/+ mice^[3].
PF 04531083 (30 min before test) improves behavioral abnormalities associated with Pitt-Hopkins syndrome (PTHS) in Tcf4^tr/+ mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Tcf4^+/+ and Tcf4^tr/+ mice ^[3]
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection (i.p.), 1.5 h before test
Result:	Decreased episodes of hyperventilation, increased the occurrence of spontaneous sighs, diminished duration of post-sigh apnea and improved the CO₂ minute ventilatory response in Tcf4^tr/+ mice. Showed stable respiratory activity in Tcf4^+/+ mice. Showed a robust increase in respiratory activity (62.5% increase in minute ventilation from 3 to 7% CO₂) in Tcf4^tr/+ pups.

Ensayo clínico

Peso molecular

357.79

Fòrmula

C₁₇H₁₆ClN₅O₂

No. CAS

1079400-07-9

Appearance

Solid

Color

Light yellow to yellow

SMILES

ClC1=CC=C(OC)C=C1C2=C(N=C(NC(C3=CC=NN3C)=O)C=C2)N

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (279.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7949 mL	13.9747 mL	27.9494 mL
5 mM	0.5590 mL	2.7949 mL	5.5899 mL
10 mM	0.2795 mL	1.3975 mL	2.7949 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.62%

Select Batch:

Ficha de datos (279 KB) SDS (393 KB)

COA (254 KB) LCMS (102 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Yekkirala AS, et al. Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov. 2017 Aug;16(8):545-564. [Content Brief]

[2]. Bagal SK, et al. Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain. ACS Med Chem Lett. 2015 Apr 29;6(6):650-4. [Content Brief]

[3]. Cleary CM, et al. Disordered breathing in a Pitt-Hopkins syndrome model involves Phox2b-expressing parafacial neurons and aberrant Nav1.8 expression. Nat Commun. 2021 Oct 13;12(1):5962. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7949 mL	13.9747 mL	27.9494 mL	69.8734 mL
	5 mM	0.5590 mL	2.7949 mL	5.5899 mL	13.9747 mL
	10 mM	0.2795 mL	1.3975 mL	2.7949 mL	6.9873 mL
	15 mM	0.1863 mL	0.9316 mL	1.8633 mL	4.6582 mL
	20 mM	0.1397 mL	0.6987 mL	1.3975 mL	3.4937 mL
	25 mM	0.1118 mL	0.5590 mL	1.1180 mL	2.7949 mL
	30 mM	0.0932 mL	0.4658 mL	0.9316 mL	2.3291 mL
	40 mM	0.0699 mL	0.3494 mL	0.6987 mL	1.7468 mL
	50 mM	0.0559 mL	0.2795 mL	0.5590 mL	1.3975 mL
	60 mM	0.0466 mL	0.2329 mL	0.4658 mL	1.1646 mL
	80 mM	0.0349 mL	0.1747 mL	0.3494 mL	0.8734 mL
	100 mM	0.0279 mL	0.1397 mL	0.2795 mL	0.6987 mL

PF 04531083 Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PF 045310831079400-07-9PF04531083PF-04531083Sodium ChannelNa channelsNa+ channelsinflammationrespiratoryblood-brain barrierInhibitorinhibitorinhibit

Productos vistos recientemente:

Nombre del producto

Requested Quantity *

Nombre del solicitante *

Saludo

Direcciòn del E-mail *

Número de teléfono *

Department

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

Observaciones

Nombre del producto

Lot #

Nombre del solicitante *

Direcciòn del E-mail *

Número de teléfono

Department *

Nombre de la Organizaciòn *

Country or Region *

Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

PF 04531083

Revisión del cliente

Other Forms of PF 04531083:

PF 04531083 Related Antibodies

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Sodium Channel:

Actividad biológica

Pureza y Documentación

Referencias

Revisión del cliente

PF 04531083 Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

PF 04531083 Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report